Anavex Life Sciences Corp (AVXL)

[kspar1]

Exactly! We all are in control of our knowledge and behaviors. Now where's that bottle of wine I opened earlier today?

[kund]

Enjoy your weekend.

[Pazzo1212]

Yeah, I’ve played that game. But happy where we are

[ignatiusrielly35]

Why didn’t I sell at 30=why didn’t I buy at 3.60? Psychology 101.

[Pazzo1212]

Me too! 5,500 shares.

[ignatiusrielly35]

Added today. Don’t care if I caught the bottom. Chicken feed in the big picture view.

[poguemahone]

Oh yes, the WWS (Wild Weekend Speculation) posts are in full swing. Too bad Monday morning 9:30 am arrives, and reality smacks you right between the eyeballs.

Missling talks a big game, but his actions (or lack thereof) these past 9 years are a sobering reality of why the SP is sub 4.

[bb8675309]

$100 per share or $8 Billion MC is a cheap price with current drug trial results we know today. imo. Incredible...

[kund]

Another delusional pumper. Check his record, he writes on SA under "The Political Economist".

In Jan 2023 he wrote "Approval for AVXL-2-73 looks inevitable...." In Nov 2023 "How soon Anavex's drug be approved..."

The entire WGT crowd full of conspiracy mindset, this company and drug is worthless because of clown ceo, who spends 364 days with model in Europe, he designed useless tiny trials using "Super Responder" buzzword.

[tredenwater2]

This guy is spot on George. Thanks for the link. Not sure how many people he reaches with only 21 followers but this s what we will see after the peer reviewed paper and as we get closer to approval. Ut will be a COMPLETE reversal and a “uh duh” moment in history when time stands still as the shot will be heard around the world! Make your nickels and dimes now cause this is going up in the coming months.

Also Kudos to Dr. Missling for being steady at the helm during multiple storms.

Blessings

Tred

[georgejjl]

BREAKING: Anavex’s Blarcamesine reduces plaque in Alzheimer’s brains without dangerous side effects

From ST

https://medium.com/@irwinbooks/breaking-anavexs-blarcamesine-reduces-plaque-in-alzheimer-s-brains-without-dangerous-side-effects-df893e362a37

Good luck and GOD bless,

[crescentmotor]

Put yourself in the role of an investor.

Stock basher--you sell nothing but hogwash. Real investors do not base stock buying decisions based on analyst price targets. I've owned many stocks and have only given a passing glance, if any, at price targets. Serious investors conduct thorough due diligence into fundamentals of the business including that of competitor companies. I have never known anyone to base a stock purchase decision on the opinion of a stock analyst just because of what you posted; that is, just about all of them have bad track records. You're full of shat.

[LakeshoreLeo1953]

Are you a member of BSIG?

[kund]

Yet another useless patent. I remember countless discussions on this board back in 2015-2017 about Anavex's patent, super responders from tiny OL trial sparking euphoria and everyone counting their chips. But a patent only holds value if the drug proves effective in clinical trials; otherwise, it's as worthless as toilet paper. At this point, all of Anavex's patents are nothing more than toilet paper. Mf Misleading knows this, he is using buzzwords to keep WGT crowd hooked to kool-aid.

[georgejjl]

Anavex Life Sciences gets grant for treatment/prevention of pain using AV1066 dosage form

https://www.pharmaceutical-technology.com/data-insights/anavex-life-sciences-gets-grant-for-treatment-prevention-of-pain-using-av1066-dosage-form/?utm_source=lgp6-patents-grant&utm_medium=24-295791&utm_campaign=recommended-articles&cf-view

Good luck and GOD bless,

[georgejjl]

Citi Group adds 465K shares of AVXL shares last qtr. from ST

Good luck and GOD bless,

[BIOChecker4]

You are very naive. From Life On The Buy Side: “Sell side equity research makes money indirectly, primarily through commissions generated when the buy side trades through the sell side trading desks.”

See this link for additional information: https://www.lifeonthebuyside.com/life-on-the-sell-side-equity-research/#:~:text=Sell%20side%20equity%20research%20makes,the%20sell%20side%20trading%20desks.

Put yourself in the role of an investor. You’re thinking about buying a stock currently trading at say $4.00. Analyst A at firm A has a 12-month price target $8. Analyst B at firm B has a price target of $32. Which firm would you be more likely to buy through? The one with a $8 price target or the one with a $32 price target?

Look at the track record of a bunch of analysts. Most are more often wrong than right. For example, look at the track record of Soumit Roy at Jones Trading. His success rate is just 28%! https://www.tipranks.com/experts/analysts/soumit-roy

Next, look at the track record of Ram Selvaraju at HC Wainwright. His success rate is just 53% (basically a coin toss). https://www.tipranks.com/experts/analysts/ram-selvaraju

So ask yourself, How do these analysts stay employed? Clearly it’s not because they have such great track records of accurate forecasts. No. The answer is that they are very good at generating significant revenues for their firms and they are paid accordingly. It isn’t the accuracy of the price target that matters. It’s how adept they are at bringing in trading revenue.

[kund]

Another market expert. It seems like IHUB pumpers, especially from scam stocks like NWBO and Avxl, want to dictate the share price. Perhaps you all can join forces and cook a scheme to achieve that.

[Chemdeps]

I have some dry powder coming soon....hoping I can catch these low prices before any of the moves you described take place.

[Lacey1]

You are correct, we are orders of magnitude undervalued. Will correct itself in time. Hedge funds are 10's of billions in size. They plug in their "lower the price algorithms" and walk the price down, trying to get impatient retail to sell shares.

Have patience, Don't listen to the 43 shorts on this board.

[skitahoe]

It's my belief that Market Cap is related to the perception of when approval, and therefore revenue, can be anticipated. The market cap should move up dramatically as more becomes known, from the issuance of the Journal, and then a filing is made with at least one, or perhaps more, of the regulators. In anticipating approval short term, the market cap ought to be in at least the billion dollar range, then post approval rising revenue will take it substantially higher.

It's my belief that if the perception is that our drugs will eventually be approved for many diseases, the P/E for the company should be in the 30 area, IE on the high side of the revenue multiples. I certainly believe that with approvals our revenue will go into multiple billions annually, with a P/E of 30 a market cap at or near triple digit billions is certainly in the realm of possibilities. It won't happen instantly, but if the company isn't bought out, it should happen in time.

Gary

[nidan7500]

I'm at a loss..the market does not always make sense, but either something is amiss or we are undervalued by orders of magnitude.

Thehubby

Agree

[Reyeton]

That’s a lot of shares. I cannot totally believe Missling is as corrupt as he sometimes appears to be. Lack of transparency, missed deadlines and a seeming lack of ability to capture the talent of those he surrounds himself with certainly doesn’t add credibility to his resume. But, with that being said, there does seem to be changes happening in the FDA that could boost our chances of approval in the not too distant future. Rett and AD are still on the table, according to Missling. If they somehow find a way to cross the finish line with A2-73, 50 bucks per share will look like pocket change. All my personal opinion, fwiw, so don’t take it as investment advice. Maybe Missling will taper his ego a bit and let the professionals around him do their job.

[skitahoe]

My problem with many analysts comes when their targets are hit. Often they will lower their rating to hold and announce new buy ratings rather than setting new targets for the stock. If the stock doubled, they take full credit, after all, they said hold. Where do they think the money comes from when they say buy this, but hold that?

To me, a good analyst reexamine a stock when a target is met. At that point, either a new higher target should be set, or if no further growth is seen for awhile the rating should move to sell.

Most analysts are pushing the stocks their brokerage tells them to, little of their own thoughts apply unless they are independent of a brokerage.

Gary

[ExtremelyBullishZig]

Nope...just inching toward the true value of Anavex...he still has a mile to go before getting an accurate prediction.

[WolfofMia]

Only ppl who respect him are the ones paying.

[Thehubby]

I'm being an open book...
I own 37,500 shares.
I do not understand how shares can be $3.80 after our CEO, love him or not, stated that they were asked/told to apply for use by the EMA
for Alzheimers???
Shouldn't we be at $50??

I'm at a loss..the market does not always make sense, but either something is amiss or we are undervalued by orders of magnitude..I'm hoping for the latter

[kund]

This dog has fleas....careful with your money, never trust a CEO who lies and lies in every CC.

[crescentmotor]

Analysts set high price targets in order to generate investor interest and trading across their firms’ platforms.

As is routinely disclosed, analysts typically set one year price targets. So your view is that those targets are set artificially high to attract business and those analysts don't mind looking like fools when the targets are not met? It is certainly true that rating firms publicly follow companies with the hopes of furnishing investment banking services in the future but it doesn't make sense that these firms and their analysts don't have reputational restraints that govern their work so I don't buy your theory at all.

[BIOChecker4]

“Most brokerage firms pressure analysts not to post targets more aggressively than that unless there is an immediate catalyst on the horizon.”

Complete made-up nonsense. It’s actually the exact opposite. Analysts set high price targets in order to generate investor interest and trading across their firms’ platforms.

[tradersbend]

You should sell half and invest in Johnson & Johnson (no more tears)

[tredenwater2]

“ Even more importantly for holders, once the milestone of filling at the EMA has been reached (and expectations of a similar filing at the FDA gain in credibility), new sell side analysts will step up to the plate and carry the weight of more substantive firms than Jones Trading.”

William, if you add to hat the third party peer reviewed publication in a top medical journal, how can these analysts NOT raise their price targets? How much more will need to be presented before the “fair and balanced” market folds in defeat that a tiny out of know where biotech has “defeated” Alzheimer’s and quite possibly symptomatic relief for many many more diseases?

What a great lesson learned about truth, above and beyond and nickels and dimes tucked under the pillow if that silk casket.

Cheers

[kund]

Maybe he's finally realized the truth about the drug and the incompetent CEO....

[nidan7500]

WilliamMunny

Even more importantly for holders, once the milestone of filling at the EMA has been reached (and expectations of a similar filing at the FDA gain in credibility), new sell side analysts will step up to the plate and carry the weight of more substantive firms than Jones Trading.

Thanks for this analysis of the trading process.

Sadly, What you describe presents no direct links to the medical benefits derived by patient or their families (re: if this then...). Wow. Not saying your are wrong on the process of what will/might happen, Just more evidence to consider on how corrupt WS really is.

[bas2020]

Apparently, he's now figuring in the collusive stock manipulation, which is finally evident to him.

Didn’t he have a $40 target 6 months ago?

[WilliamMunny]

Power, I would simply say that if he is setting a target price of roughly 3x the current price, he is quite bullish. Most brokerage firms pressure analysts not to post targets more aggressively than that unless there is an immediate catalyst on the horizon. Like yourself, most holders who understand the dynamics here understand that once an MAA has been filed and accepted, AVXL will be trading comfortably above that $15 level. In response to that move, Summit Roy can claim victory and then set a new target of $45 (or whatever). More trades will be generated on the news and the firm's response. That is how the game is played. Even more importantly for holders, once the milestone of filling at the EMA has been reached (and expectations of a similar filing at the FDA gain in credibility), new sell side analysts will step up to the plate and carry the weight of more substantive firms than Jones Trading.

[poguemahone]

I agree with your assessment of malfeasance. He keeps promising, but never delivers. Even if he is not a crook (to be determined), he sure acts like one. The only achievement he has made to date (other than self enrichment) is the undermining of any credibility this company once had. For these reasons alone he should have been fired already.

[boi568]

You don't seem to understand why there are clinical trials -- it's to get approval from the FDA (or counterparts). A clinical trial that leads to an FDA approval is a successful clinical trial.

[poguemahone]

Didn’t he have a $40 target 6 months ago? Now Missling’s biggest cheerleader is down to $15?

Even Soumit can’t put lipstick on this pig.

[Anshu2]

You don’t know much about clinical trials; really.

FDA’s guidance on endpoints has no relevance to success or failure of trials — only on their approval chances, if any.

[kund]

where is that $1248 guy? Is he dead?

[mrplmer]

PW you might not of listened to the call yesterday.

Normally analyst targets are for a year.

When Missling announced EMA he said the plan would be as ealy as possible in 2024. Yesterday he said by the end of the year more than once.

Remember Jin was on board in Jan of 23.

Yesterday he hinted because of new FDA rules using 1 biomarker, there could be multiple submissions.

Now we know if it takes EMA 7 submission a year then how could they submit to FDA at the same time.

So $15.00 is a annual target and I doubt they get EMA in by December.
I've been an investor for 50 years. I've never seen such malfeasance and lack of transparency in all those years. I might be better off in the lawsuit at $31.50 plus punitive damages if I'm looking at $15.00.

[powerwalker]

... and has a $15.00 price target.

mrp, did he state why $15? Is that for what time period? End of June, July, August, September, 2024, 2025?

One would think that if it goes up ~300% that there were positive news and if so, that news moves it up more than ~300%.

[mrplmer]

just bringing reality to the WGT and Fritzy fans. What has he accomplished in 8 years that would allow him to have that kind of option load.

[LakeshoreLeo1953]

$4 to $13 would be an important retrace and potentially
get many here even....at least for hoooooold looooong shares over two years.
Not sure about new Asian investments around the 12-13 FOMO action.

I'll still await others to break $4 on volume before gambling.
Seems 2025 is a better bet above $10 than this fiscal year.

[plexrec]

mrp--"and has a $15.00 price target."--better than a poke in the eye !!!!!

[mrplmer]

Anavex Life Sciences (AVXL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading reiterated a Buy rating on the stock and has a $15.00 price target.

[sumbuysumsell]

$1248 + Dividends. Probably before year end.

Lol.

😜

[mike_dotcom]

I guarantee you it will be closer to 3.88 than 388. Quit being delusional. This is turning out to be the worst piece of schitt I've ever invested in and I've invested in quite a few. Down again today - down almost every day. Nothing ever changes.

[nidan7500]

$388...more like it.